Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy

被引：0
|
作者：
Dellepiane, C. [1 ]
Coco, S. [1 ]
Dal Bello, M. G. [1 ]
Rossi, G. [1 ]
Rijavec, E. [2 ]
Biello, F. [3 ]
Tagliamento, M. [1 ]
Longo, L. [1 ]
Mora, M. [4 ]
Anselmi, G. [4 ]
Alama, A. [1 ]
Bennicelli, E. [1 ]
Grossi, F. [2 ]
Zullo, L. [1 ]
Beshiri, K. [1 ]
Bottini, A. [1 ]
Pronzato, P. [1 ]
Genova, C. [1 ]
机构：
[1] IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy
[3] Azienda Osped Univ Maggiore Carita, Med Oncol Unit, Novara, Italy
[4] IRCCS Osped Policlin San Martino, Pathol Unit, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318P
引用
收藏
页码：S851 / S851
页数：1
相关论文
共 50 条
  • [31] Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).
    Nandimandalam, Sujitha
    Sharma, Nitika
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Clinical presentation and prognosis of high PD-L1 expressors in non-small cell lung cancer
    Chin, I. S.
    Yip, K. P.
    Middleton, G.
    LUNG CANCER, 2019, 127 : S66 - S66
  • [33] Predictive and prognostic relevance of PD-L1 and TIGIT expression in patients with non-small cell lung carcinoma treated with immunotherapy
    Zgubic, J. A.
    Zacharias, M.
    Wurm, R.
    Terbuch, A.
    Brcic, L.
    HISTOPATHOLOGY, 2022, 81 : 170 - 170
  • [34] Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
    Eltahir, Mohamed
    Isaksson, Johan
    Mattsson, Johanna Sofia Margareta
    Karre, Klas
    Botling, Johan
    Lord, Martin
    Mangsbo, Sara M.
    Micke, Patrick
    CANCERS, 2021, 13 (13)
  • [35] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Qu, Jingjing
    Mei, Quanhui
    Liu, Li
    Cheng, Tianli
    Wang, Peng
    Chen, Lijun
    Zhou, Jianying
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [36] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
    Jiang, Liyan
    Su, Xinying
    Zhang, Tianwei
    Yin, Xiaolu
    Zhang, Meizhuo
    Fu, Haihua
    Han, Hulin
    Sun, Yun
    Dong, Lili
    Qian, Jialin
    Xu, Yanhua
    Fu, Xuan
    Gavine, Paul R.
    Zhou, Yanbin
    Tian, Kun
    Huang, Jiaqi
    Shen, Dong
    Jiang, Haiyi
    Yao, Yihong
    Han, Baohui
    Gu, Yi
    ONCOTARGET, 2017, 8 (16) : 26845 - 26857
  • [37] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [38] Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC)
    McLaughlin, Joseph Francis
    Schaiper, Kurt
    Carvajal-Hausdorf, Daniel E.
    Velcheti, Vamsidhar
    Haack, Herbert
    Silver, Matthew
    Goldberg, Sarah B.
    Herbst, Roy S.
    Rimm, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [40] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
12345